Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Arrive AI (NASDAQ:ARAI) Clears a Repayment Trigger, So Is Autonomous Delivery Ready to Reaccelerate?

Arrive AI (NASDAQ:ARAI) is trying to buy itself time and momentum at the same time. The autonomous last-mile delivery company, known for its 'Arrive Point' smart-mailbox infrastructure, moved in August 2026 to cut costs and defuse a financing pressure point, while continuing to sign …

Vinay Lochav | 27 August 2026

Can New Government Contracts Push Cyabra (NASDAQ:CYAB) Into Breakout Mode?

Cyabra (NASDAQ:CYAB) is a newly public company operating in a market that has never been more topical: detecting disinformation, fake accounts and coordinated online manipulation. Since itsNasdaqdebut earlier in 2026, the AI-driven data-intelligence firm has been signing customers across government and enterprise, and a …

Vinay Lochav | 27 August 2026

Angi (NASDAQ:ANGI) Widens Its Loss: Is a Turnaround Closer Than It Looks?

Angi (NASDAQ:ANGI), the home-services marketplace that connects homeowners with contractors, reported a second quarter that widened its loss, even as management pointed to strategic progress in AI and its largest professional customers. Now trading as an independent company after its separation from IAC, Angi …

Vinay Lochav | 27 August 2026

Could VolitionRx's (NYSE American:VNRX) Sepsis Validation Mark a Commercial Turning Point?

VolitionRx (NYSE American:VNRX) is pressing to convert years of research into commercial reality, and a string of August 2026 announcements has put its Nu.Q epigenetics platform back in the spotlight. The diagnostics company, which develops blood-based tests built around nucleosome measurement, highlighted new clinical …

Vinay Lochav | 27 August 2026

Can Synergy CHC (NASDAQ:SNYR) Survive a Fresh Default Notice on Its Term Loan?

Synergy CHC Corp. (NASDAQ:SNYR) has run into a serious balance-sheet problem. The consumer health and wellness company, known for brands in the nutrition and supplement space, disclosed in an August 2026 regulatory filing that it had received a notice of default on its term …

Vinay Lochav | 27 August 2026

Upstream Bio (NASDAQ:UPB): What's at Stake as Verekitug Awaits Pivotal Data?

●UpstreamBio reported a net loss of about $39.7 million reflecting its clinicalInvestmentand a Phase 3 development strategy targeting 2027.

Vinay Lochav | 27 August 2026

ARS Pharmaceuticals (NASDAQ:SPRY): Can neffy's Launch Build Into a Breakout Story?

● neffy is a needle-free epinephrine nasal spray for severe allergic reactions, an alternative to traditional auto-injectors.

Vinay Lochav | 27 August 2026

Senti Biosciences (NASDAQ:SNTI): What's Next for Its Gene-Circuit Cell Therapy Platform?

● Senti's lead candidate, SENTI-202, is a gene-circuit CAR-NK cell therapy aimed at relapsed or refractory acute myeloid leukemia.

Vinay Lochav | 27 August 2026

Can a Pivotal Liver Cancer Readout Turn Around Tvardi Therapeutics (NASDAQ:TVRD)?

Tvardi Therapeutics (NASDAQ:TVRD) is at the stage every clinical biotech must eventually reach: the point where pipeline promise meets the hard arithmetic of cash and catalysts. The company, which develops orally available small-molecule STAT3 inhibitors, updated investors in mid-August 2026 with aBusinessreview that laid …

Vinay Lochav | 27 August 2026
Support

Hi! How can we help you today?

Loading…